LAUSANNE, Switzerland–(BUSINESS WIRE)–Novigenix SA, a leading Immuno-Transcriptomics company that develops and
commercializes products for early cancer detection and precision
medicine, today announced the appointment of Francois Martelet, M.D., to
its Board of Directors as a non-executive director. Dr. Martelet has
over 25 years’ experience at both corporate and operational level in
pharmaceutical and biotech companies.
“Francois is a proven leader, who has guided multiple international
pharma and biotech companies in his career. In particular, his recent
experience with diagnostic companies and shared vision will prove
invaluable to Novigenix as we build our Immuno-Transcriptomics based
diagnostics portfolio. We sincerely welcome him to the company,” said
Dr. Jan Groen, CEO of Novigenix.
“Novigenix’s unique Blood Immuno-Trancriptomics sequencing platform
(BITseq™) provides a new avenue to the development of diagnostics to
detect cancer at the early stages as well as intriguing applications in
precision medicine. I look forward to working with the whole team at
this pivotal time,” said Dr. Martelet.
Dr. Martelet recently retired as CEO of NetScientific, a publicly listed
healthcare investment group in the UK focused on diagnostics, digital
health and therapeutics. As part of his CEO role, Francois was Chairman
of several companies, including Vortex BioSciences, Wanda, Glycotest and
ProAxsis. Dr. Martelet held several executive positions, such as CEO at
Topotarget, a publicly traded oncology therapeutics company, which was
successfully merged with BioAlliance. He also held senior level
commercial roles in oncology at Novartis Pharma AG and Merck & Co, Inc.
Dr. Martelet earned a Doctorate in Medicine and a Master’s in Business
from Dijon University (France). He also holds a Degree in Legal Medicine
from R. Descartes University School of Medicine (Paris, France). In
addition, he is a graduate of the Advanced General Management Program at
INSEAD (France) and attended several Senior Executive Programs at
Harvard Business School (Boston, USA).
“I am delighted to welcome Dr. Martelet as a new director to our Board,”
said Dr. Brian Hashemi, Executive Chairman of the Board. “Martelet’s
extensive medical oncology and operational experience within
pharmaceutical and biotech companies throughout the world will
definitely bring tremendous advantage to Novigenix as we expand
applications of our BITseq™ platform.”